晚期非小细胞肺癌患者接受盐酸安罗替尼一线和二线治疗的近期疗效观察
Short-term efficacy of first-and second-line anlotinib therapy in patients with advanced non-small cell lung cancer
王敏 1常宁 1张勇 1张艰1
作者信息
- 1. 空军军医大学西京医院呼吸与危重症医学科,陕西西安 710032
- 折叠
摘要
目的 探讨无法接受化疗或靶向治疗的晚期非小细胞肺癌(NSCLC)患者在应用安罗替尼作为一线和二线治疗时的近期疗效和安全性评价,分析治疗线数与预后的潜在相关性.方法 收集接受化疗或靶向治疗并接受安罗替尼单药治疗的Ⅲ/Ⅳ期NSCLC患者临床信息并进行回顾性分析,共纳入69例符合入组要求的Ⅲ/Ⅳ期NSCLC患者,其中26例从未接受过抗肿瘤治疗的患者使用安罗替尼一线治疗(一线治疗组),43例化疗不耐受或靶向治疗耐药的患者接受安罗替尼二线治疗(二线治疗组).上述患者无进展生存期(PFS)为主要评价指标,次要观察指标包括客观缓解率(ORR)、疾病控制率(DCR)以及安罗替尼的安全性等.结果 69例患者的中位PFS为4.6个月(95％CI:4.21～5.00),ORR 和 DCR 分别为 15.9％和 84.1％.其中,26 例接受安罗替尼一线治疗患者的ORR和DCR分别为26.9％和84.6％,43例接受安罗替尼二线治疗患者的ORR和DCR分别为9.3％和83.7％.在本研究中,安罗替尼常见的毒副反应是可控的,如高血压、手足综合征和口腔黏膜炎等.结论 安罗替尼对未接受过化疗或靶向治疗的Ⅲ/Ⅳ期NSCLC患者显示出初步的疗效和可耐受的安全性,安罗替尼的治疗线数可以作为PFS的独立影响因素.
Abstract
Objective To evaluate the short-term efficacy and safety of anlotinib as first-and second-line therapy in patients with advanced non-small cell lung cancer(NSCLC)who cannot receive chemotherapy or targeted treatment,and to analyze the potential correlation between the number of treatment lines and prognosis.Methods The clinical data of stageⅢ/Ⅳ NSCLC patients who were treated with chemotherapy or targeted therapy and anlotinib as monotherapy were collected for retrospective analysis.A total of 69 stage Ⅲ/Ⅳ NSCLC patients who met the inclusion requirements were included,among which 26 patients who had never received antitumor therapy received first-line treatment of anlotinib(first-line treatment group),and 43 patients who were intolerant of/refractory to chemotherapy or targeted therapy received second-line treatment of anlotinib(second-line treatment group).Progression-free survival(PFS)of patients was the primary evaluation index,and the secondary observation indexes included objective response rate(ORR),disease control rate(DCR),and safety of anlotinib.Results The median PFS of 69 patients was 4.6 months(95％CI:4.21-5.00),and ORR and DCR were 15.9％and 84.1％,respectively.Among them,the ORR and DCR of 26 patients receiving first-line treatment of anlotinib were 26.9％and 84.6％,respectively.The ORR and DCR of 43 patients receiving second-line treatment of anlotinib were 9.3％and 83.7％,respectively.In this study,the common toxic and side effects of anlotinib were controllable,such as hypertension,hand-foot syndrome and oral mucositis.Conclusion Anlotinib has shown preliminary efficacy and tolerable safety in stage Ⅲ/Ⅳ NSCLC patients who have not received chemotherapy or targeted therapy,and the number of treatment lines of anlotinib can serve as an independent influencing factor for PFS.
关键词
非小细胞肺癌/抗血管生成治疗/安罗替尼/治疗线数/毒副反应Key words
non-small cell lung cancer/antiangiogenic therapy/anlotinib/number of treatment lines/toxic and side effects引用本文复制引用
基金项目
国家自然科学基金(81773153)
国家自然科学基金(81902316)
出版年
2024
国家科技期刊平台
NSTL
维普
万方数据